SCHEMBL22441289

SCHEMBL22441289

[CH2]NC12CC(C1)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22441287 0.87 GRIN2D (0.52)
SCHEMBL23270410 0.67
SCHEMBL18232321 0.64
SCHEMBL16039854 0.64
SCHEMBL15101088 0.64
SCHEMBL19262511 0.64
Hydrochloric Acid SCHEMBL13387068 0.62
Hydrochloric Acid SCHEMBL17837966 0.62
Hydrochloric Acid SCHEMBL17582395 0.62
SCHEMBL17097898 0.59

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230114107-A1 COMBINATION ANTI-CANCER THERAPIES WITH INDUCERS OF IRON-DEPENDENT CELLULAR DISASSEMBLY FLAGSHIP PIONEERING, INC. 2023-04-13 US disclosed
US-20220002280-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2022-01-06 US disclosed
WO-2021127217-A1 COMBINATION ANTI-CANCER THERAPIES WITH INDUCERS OF IRON-DEPENDENT CELLULAR DISASSEMBLY FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2021-06-24 WO disclosed
US-11040964-B2 Compounds and methods of use Ferro Therapeutics, Inc. (US) 2021-06-22 US disclosed
US-20200299283-A1 COMPOUNDS AND METHODS OF USE BRIDGEBIO PHARMA, INC. 2020-09-24 US disclosed